Baxter Halts Novum LVP Shipments After Reports of Serious Injuries and Deaths, Stock Plummets 22%
Reuters
Nov 06
Baxter Halts Novum LVP Shipments After Reports of Serious Injuries and Deaths, Stock Plummets 22%
Baxter International Inc. has announced significant safety concerns related to its Novum LVP infusion device, following reports of inaccurate infusion rates. The company issued warning letters to customers in April and July 2025, disclosing a total of 79 serious injury reports and two patient deaths connected to the device. Despite these reports, Baxter initially continued to instruct hospitals on corrective steps rather than removing the devices from service. On July 31, 2025, Baxter voluntarily and temporarily paused all shipments and planned installations of the Novum LVP, citing quality concerns identified through customer feedback and internal data. This announcement led to a sharp decline in Baxter's stock price, falling over 22% in a single day.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Baxter International Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097398) on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.